Advancing siRNA Therapeutics for Neuropsychiatric Disease

Cognigenics is developing a platform of precision RNA therapeutics for neuropsychiatric and neurodegenerative conditions. Each candidate is built on our core technology: short interfering RNA (siRNA) delivered via intranasal lipid nanoparticles (LNPs), enabling targeted receptor modulation in the brain without systemic exposure.

Our lead candidate, COG-301, exemplifies this strategy. It is currently being developed for Parkinson’s Disease Psychosis with Anxiety, an area of high unmet medical need with limited therapeutic options.

Pipeline Overview

* Pipeline programs under preclinical investigation for future expansion. Subject to refinement as clinical data emerges.

Lead Candidate: COG-301

COG-301 is a weekly siRNA therapeutic targeting 5-HT2a, a receptor implicated in the limbic hyperactivity seen in Parkinson’s Disease Psychosis. Our goals:

• Selective gene silencing without the side effects of systemic antipsychotics
• Durable symptom relief without sedation or tolerance
• Noninvasive, intranasal dosing suitable for at-home administration
• COG-301 is being developed under a neurology/psychiatry regulatory path, with plans for first-in-human trials following IND-enabling studies in 2025.

Platform Expansion

While COG-301 leads our clinical path, our siRNA + LNP platform is designed to be modular and scalable. Future programs will address:

• Cognitive impairment in aging and early neurodegeneration
• Anxiety spectrum disorders across populations
• Genetic modulation of other serotonin, glutamate, or GABA receptor subtypes

Our pipeline reflects not only individual therapeutics but a broader strategy to redefine neuropsychiatry through gene-level control.